CA-RESMED
20.1.2020 15:02:08 CET | Business Wire | Press release
ResMed (NYSE: RMD) (ASX: RMD) today introduced AirFit F30i, its first tube-up full face CPAP mask, rounding out the most complete full face mask portfolio on the market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200120005042/en/
Full face CPAP users can now choose between a tube-up or tube-down connection, compact under-the-nose or traditional over-the-nose cushion styles, and even memory foam versus silicone cushion.
AirFit F30i’s tube-up design makes it easier to sleep in any position. The cushion rests under the nose to help prevent next-day red marks, soreness, and irritation on the nasal bridge. Plus, a quick-release elbow allows users to quickly disconnect and reattach the mask from its tubing at night without taking the mask off.
Three out of four CPAP users prefer AirFit F30i to its competitor’s tube-up full face mask for overall performance in a direct comparison study. Those same users preferred AirFit F30i’s seal nearly 2 to 1 and comfort nearly 3 to 1. ResMed credits AirFit F30i’s strong favor to years of research and development into the preferences of patients and HME providers.
“ResMed has the right mask for every CPAP user,” said Jim Hollingshead, president of ResMed’s Sleep business. “AirFit F30i provides a reliable seal and a comfortable under-the-nose fit for active sleepers who need a full face mask but want the flexibility of a tube-up design. AirFit F30i rounds out our world-leading portfolio of full face masks designed to meet patients’ and HME providers’ every need.”
AirFit F30i also completes ResMed’s “Freedom” category of tube-up masks, offering an option for every CPAP user. The nasal tube-up AirFit N30i came out in January 2019 and the nasal pillows tube-up AirFit P30i arrived in April.
AirFit F30i is now available in the United States, Canada, and most of Europe, with other countries to follow.
About ResMed
At ResMed (NYSE: RMD) (ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200120005042/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Parse Biosciences and Nomic Announce 100 Million Cell, Multimodal AI-ready Dataset for Immune Biology29.10.2026 13:00:00 CET | Press release
Licensable perturbation dataset to include transcriptomes and proteomic secretomes for understanding the human immune response Parse Biosciences, the leading provider of scalable and accessible single-cell sequencing and a QIAGEN company, and Nomic Bio, a leader in high throughput proteomic profiling, today announced their partnership to generate Cascade, a 100 Million cell foundational dataset to understand the human immune response. The dataset's scale and depth will give pharma partners cellular- and protein-level insight into immune biology, accelerating their ability to identify and validate new drug targets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029559438/en/ Cascade has already drawn foundational partner commitments from leading pharmaceutical and biotechnology companies, including GSK, Pfizer, Sanofi, Graph Therapeutics, and Turbine, underscoring the demand for large-scale, multimodal immune data in drug
CSC Named Winner of the Top InfoSec Innovator Award for Most Innovative DNS Security29.10.2026 13:00:00 CET | Press release
CSC’s Subdomain Monitoring recognized for innovation in mitigating subdomain hijacking risks from dangling DNS CSC, an enterprise-class domain registrar and world leader in mitigating brand, fraud, domain, and Domain Name System (DNS) threats, today announced that its Subdomain Monitoring solution took top honors for Most Innovative DNS Security in Cyber Defense Magazine’s 2026 Top InfoSec Innovator Awards. CSC introduced Subdomain Monitoring after analyzing close to half a million DNS records and finding that many companies were exposed to subdomain takeovers due to dangling DNS. CSC’s solution helps enterprises reduce this risk and secure their online ecosystems. It was the first and only technology on the market to ease the burden of tracking and maintaining DNS records and purging unused zone records to prevent subdomain hijacking. Subdomain Monitoring, powered by CSC’s one-of-a-kind DomainSecSM threat intelligence platform, alerts DNS administrators and security engineers when it
Two Single-Pill Triple Combination Lipid-Lowering Therapy Applications Validated in The European Union29.10.2026 12:27:00 CET | Press release
EMA has validated two marketing authorization applications from Daiichi Sankyo in the EU for single-pill triple-combinations of established lipid-lowering agents: bempedoic acid, ezetimibe, and either atorvastatin or rosuvastatin If approved, the proposed therapies could be the first oral single-pill triple-combinations for lipid-lowering in the EU, aiming to simplify treatment for patients requiring multiple lipid-lowering agents The submissions reflect the commitment of Daiichi Sankyo to addressing unmet needs in cardiovascular disease The European Medicines Agency (EMA) has validated two marketing authorization applications (MAA) from Daiichi Sankyo (TSE: 4568) for oral, single-pill triple-combination therapies. The applications seek approval for the treatment of adults with primary hypercholesterolemia or mixed dyslipidemia to reduce low-density lipoprotein cholesterol (LDL-C) levels and cardiovascular (CV) risk. Despite the availability of effective therapies, treatment discontinu
NIQ and Google Partner to Advance Agentic Commerce29.10.2026 11:45:00 CET | Press release
Built with Google Cloud and Gemini for business, NIQ and Google commit to transforming AI-driven product discovery, availability, and measurement Today, NielsenIQ (NYSE: NIQ) and Google announced a broad collaboration to advance agentic commerce, aiming to bring NIQ’s global retail and product intelligence together with Google’s AI commerce ecosystem to improve product discovery and local availability. NIQ and Google are looking to complement Google's extensive Shopping Graph of more than 60 billion product listings with NIQ’s Commerce Intelligence. NIQ is also naming Google Cloud as a primary AI and cloud services provider, and plans to deploy Gemini for business across its global workforce. As AI evolves from helping consumers discover products to recommending and purchasing them, brands and retailers increasingly rely on trusted product information, real-world availability, and measurement. The partnership is designed to help make agentic commerce even more reliable and measurable,
TradeStation Europe Expands Options Capability, Including Extended-Hours Trading29.10.2026 11:43:00 CET | Press release
Expanded intraday and options trading capability, combined with lower options and equities commissions across the Netherlands and the EEA TradeStation Europe B.V. (“TradeStation Europe”), the recently licensed European brokerage subsidiary of TradeStation Group, Inc. (“TradeStation”), today announced a round of product updates, including extended-hours options trading, along with reduced options and equities pricing, new single-stock option spreads and expanded intraday trading to enhance the offering for retail and institutional traders across the Netherlands and the European Economic Area (EEA). Extended-hours options trading is now live. Clients can trade eligible equity options during a pre-market session from 7:30 a.m. to 9:25 a.m. ET and an extended curb session from 4:00 p.m. to 4:15 p.m. ET. The launch follows Cboe Global Markets, Inc.’s (Cboe: CBOE) introduction of extended trading hours for options on 24 individual stocks and five ETFs, expanding access to some of the most ac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom